Important Information for Intellia Therapeutics, Inc. (NTLA) Investors: Rosen Law Firm Files Securities Class Action Lawsuit
On February 27, 2025, Rosen Law Firm, a leading global investor rights law firm, announced that it has filed a class action lawsuit on behalf of purchasers of the securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”). The complaint alleges that the defendants, during the Class Period, made false and/or misleading statements and/or failed to disclose material information about Intellia Therapeutics’ business, financial condition, and prospects.
Allegations against Intellia Therapeutics
The complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose material information, including:
- Failure to disclose that the company’s CRISPR/Cas9 gene-editing technology was not as effective as claimed;
- Failure to disclose that the company’s lead product candidate, INT-200, was experiencing manufacturing issues;
- Failure to disclose that the company was facing regulatory challenges;
- Failure to disclose that the company’s financial projections were overstated;
Effect on Individual Investors
If you purchased Intellia Therapeutics securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline in this action is April 14, 2024. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2024. To join the class action, go to
Effect on the World
The allegations against Intellia Therapeutics could have far-reaching implications for the gene-editing industry as a whole. If the allegations are proven true, it could lead to increased scrutiny of other companies in the industry and potential regulatory action. Additionally, it could cause investors to become more cautious when investing in biotech companies, particularly those with unproven technologies or products.
Conclusion
If you invested in Intellia Therapeutics during the Class Period, you may be entitled to compensation. Rosen Law Firm encourages investors to contact them for more information about the class action and to learn about their options. The allegations against Intellia Therapeutics could have significant implications for the gene-editing industry and the biotech industry as a whole. As always, it’s important for investors to be vigilant and to carefully research any potential investment before making a decision.
Rosen Law Firm, P.A. is a leading global investor rights law firm, representing investors throughout the globe. The firm has secured hundreds of millions of dollars for its clients. For more information, visit
